Clinical Laserthermia Systems AB publishes interim report January – March 2023
Summary of the interim report (relates to the Group) Three months (01/01/2023–03/31/2023) · Net sales totaled SEK 587,000 (SEK 708,000). · Profit/loss after financial items totaled SEK -21,464,000 (SEK -13,842,000). · Basic and diluted earnings per share totaled SEK -0.15 (SEK -0.21). · The equity ratio at March 31, 2022, was 7,5% (12%). Significant events in the first quarter of 2023 · The twentieth and final patient was treated by the Urological Research Network, LCC, based in Florida, USA, in the phase 1 clinical trial using the CLS TRANBERG®